Third and fourth workshops of the European paediatric network for haemophilia management

Haemophilia

Volumn 9, Issue 2, 2003, Pages 223-228

  Hill, Frank G H ^a   Ljung, R ^b  

^a BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; RECOMBINANT BLOOD CLOTTING FACTOR 8;

CLINICAL PRACTICE; CLINICAL PROTOCOL; CONFERENCE PAPER; DISEASE CARRIER; DRUG MEGADOSE; EUROPE; GENE DELETION; GENE MUTATION; GENE THERAPY; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOLOGICAL TOLERANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PEDIATRICS; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; SCORING SYSTEM; WORKSHOP;

EID: 0037368541     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2003.00746.x     Document Type: Conference Paper

References (19)

1. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors - twenty years 'Bonn Protocol'. Vox Sang 1996; 70 (suppl 1): 30-5.
2. Federal Chamber of Physicians. Konsensus Empfehlungen zur Hamophiliebehandlung in Deutschland. Haemostaseologie 1994; 14: 81-3.
3. Federal Chamber of Physicians. Leitfaden zur Therapie mit Blutkomponenten und Plasmaderivaten. Germany: Arzte Verlag, 1995.
4. Brackmann HH, Lenk H, Scharrer I, Auerswald G, Kreuz W. German recommendations for immune tolerance therapy in type A haemophiliacs with anti-bodies. Haemophilia 1999; 5: 203-6.
5. Mauser-Bunschoten EP, Roosendahl G, van den Berg HM. Low-dose immune tolerance therapy: the van Creveld model. Vox Sang 1996; 70 (Suppl 1): 66-7.
6. Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg BM, Nilsson IM. Tolerance induction using the Malmo treatment model 1982-1995. Haemophilia 1999; 5: 32-9.
7. Ljung R, Petrini P, Lindgren AC, Tengborn L, Nilsson IM. Factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 1550.
8. Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
9. Addiego J, Kasper C, Abildgaard C et al. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 1993; 342: 462-4.
10. de Biasi R, Rocino A, Papa ML, Salerno E, Mastrullo L, De Blasi D. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Tbromb Haemost 1994; 71: 544-7.
11. Keeuz W, The GTH Study Group. Inhibitor incidence in previously untreated patients (PUPs) with haemophilia A and B. Presentation at the XXIIIth Int. Cong. of the World Federation of Haemophilia. May 1998 in Den Hague NL.
12. Gruppo R, Chen H, Schroth P, Bray GL for the Recombinate PUP Study Group. Safety and immunogenicity of recombinant factor VIII (recombinate) in previously untreated patients (PUPs): a 7.3 year update. Haemophilia 1998; 4: abstract 291.
13. Rothschild C, Laurian Y, Satre EP et al. French previously untreated patients with severe haemophilia A after exposure to recombinant factor VIII: incidence of inhibitor and evaluation of immune tolerance. Thromb Haemost 1998; 80: 779-83.
14. Lusher JM, Spira J, Magill M. A four-year update of safety and efficacy of a second generation B-domain deleted factor VIII (R-VIII SQ) in previously untreated hemophilia A patients. Blood 1998; 92: Abstract 2282.
15. Gringeri A, Kreuz W, Escuriola-Ettinghausen C et al. Anti-FVIII inhibitor incidence in previously untreated patients (PUPs) with hemophilia exposed to Kogenate (G.I.P.S.I. - German-Italian PUP Study on Inhibitor). Haemophilia 1998; 4: abstract 289.
16. Warrier I. Management of haemophilia B patients with inhibitors and anaphylaxis. Haemophilia 1998; 4: 574-6.
17. Attali O, Vinciguerra C, Trzeciak MC et al. Factor IX gene analysis in 70 unrelated patients with haemophilia B: description of 13 new mutations. Thromb Haemost 1999; 82: 1437-42.
18. Ljung R, Petrini P, Tengborn L, Sjorin E. Haemophilia B mutations in Sweden: a population-based study of mutational heterogeneity. Br J Haematol 2001; 113: 81-6.
19. Ljung R. Meeting report: Second Workshop of the European Paediatric Network for Haemophilia Management, 17-19 September 1998 in Vitznau/Switzerland. Haemophilia 1999; 5: 286-91.